Grants and Contributions:

Back to search

Title:

Covid 19 diagnostic

Agreement Number:

947829

Agreement Value:

$250,000.00

Agreement Date:

Apr 1, 2020 - Aug 31, 2022

Description:

A major roadblock in COVID-19 research is the lack of available reagents for research and manufacturing. The need for research reagents is urgent. AffinityImmuno has developed a very rapid turnaround immunization protocol and has the first available antibodies on the market. AffinityImmuno has raised antibodies against the full extracellular domain of COVID-19 spike protein and nucleocapsid and has the opportunity to develop critical components that will be used in R&D of diagnostic products and products that will affect the disease course. Because the antibodies were raised in chicken we have a large supply and are now working towards developing critical products in partnership with the private sector and academia.

Organization:

National Research Council Canada

Expected Results:

The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization

Location:

Brackley, Prince Edward Island, CA C1E 1C4

Reference Number:

172-2020-2021-Q1-947829

Agreement Type:

Contribution

Report Type:

Grants and Contributions

Recipient Business Number:

807019971

Recipient Type:

For-profit organization

Additional Information:

This agreement has been amended 1 time(s). The end date of this agreements has been modified by 184 days.

Amendment Date

Mar 16, 2022

Recipient's Legal Name:

AffinityImmuno Inc.

Federal Riding Name:

Malpeque

Federal Riding Number:

11004

Program:

Industrial Research Assistance Program – Contributions to Firms

Program Purpose:

Coverage:

IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.

NAICS Code:

541710

Amendments:

See Amendments